BARCELONA, Spain, June 17, 2025--(BUSINESS WIRE)--Ferrer, a B Corp-certified international pharmaceutical company, has announced that FNP-223, a novel therapy in-licensed from Asceneuron and aimed at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results